GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Piramal Pharma Ltd (BOM:543635) » Definitions » EBITDA Margin %

Piramal Pharma (BOM:543635) EBITDA Margin % : 21.07% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Piramal Pharma EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Piramal Pharma's EBITDA for the three months ended in Mar. 2024 was ₹5,378 Mil. Piramal Pharma's Revenue for the three months ended in Mar. 2024 was ₹25,524 Mil. Therefore, Piramal Pharma's EBITDA margin for the quarter that ended in Mar. 2024 was 21.07%.


Piramal Pharma EBITDA Margin % Historical Data

The historical data trend for Piramal Pharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Piramal Pharma EBITDA Margin % Chart

Piramal Pharma Annual Data
Trend Mar21 Mar22 Mar23 Mar24
EBITDA Margin %
21.24 19.37 12.72 16.75

Piramal Pharma Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.73 10.58 17.47 15.91 21.07

Competitive Comparison of Piramal Pharma's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Piramal Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Piramal Pharma's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Piramal Pharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Piramal Pharma's EBITDA Margin % falls into.



Piramal Pharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Piramal Pharma's EBITDA Margin % for the fiscal year that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Mar. 2024 )/Revenue (A: Mar. 2024 )
=13683.5/81711.6
=16.75 %

Piramal Pharma's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=5378.3/25523.6
=21.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Piramal Pharma  (BOM:543635) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Piramal Pharma EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Piramal Pharma's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Piramal Pharma (BOM:543635) Business Description

Traded in Other Exchanges
Address
Piramal Ananta, Agastya Corporate Park, Opposite Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai, MH, IND, 400070
Piramal Pharma Ltd offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 15 global facilities and a global distribution network in over 100 countries. It includes integrated contract development and manufacturing organization business, complex hospital generics business, and India consumer healthcare business, selling over-the-counter products in India.

Piramal Pharma (BOM:543635) Headlines

No Headlines